Immunovant Q2 EPS $(0.45) Beats $(0.48) Estimate; Pro Forma Cash And Cash Equivalent Of $737M
Portfolio Pulse from Benzinga Newsdesk
Immunovant reported Q2 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.48) by 6.25%. This is a 9.76% decrease over losses of $(0.41) per share from the same period last year. The company's pro forma cash and cash equivalent stands at $737M.
November 09, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immunovant's Q2 losses were less than expected, but increased compared to last year. The company's cash position is strong at $737M.
While Immunovant's Q2 losses were less than expected, indicating a positive performance, the increase in losses compared to the same period last year could be a concern for investors. However, the company's strong cash position could provide some reassurance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100